Climate Change Data

CureVac

Climate Impact & Sustainability Data (2022, 2023, 2024)

Reporting Period: 2022

Environmental Metrics

Total Carbon Emissions:Not disclosed
Scope 1 Emissions:Not disclosed
Scope 2 Emissions:Not disclosed
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:Not disclosed
Water Consumption:Not disclosed
Waste Generated:Not disclosed
Carbon Intensity:Not disclosed

ESG Focus Areas

  • Not disclosed

Environmental Achievements

  • Not disclosed

Social Achievements

  • Increased workforce from an average of 440 in 2019 to over 1000 in 2022.

Governance Achievements

  • Not disclosed

Climate Goals & Targets

Long-term Goals:
  • Not disclosed
Medium-term Goals:
  • Potentially initiate pivotal Phase 3 trial for CV0501 in 2024 (contingent on discussions with regulatory authorities).
Short-term Goals:
  • Initiate Phase 2 clinical study for CV0501 (COVID-19 vaccine) later in 2023.
  • Initiate Phase 1/2 study for multivalent Flu SV mRNA (influenza vaccine) in Q2 2023.
  • Initiate proof-of-principle study in oncology (Glioblastoma Multiforme) in Q2 2023.

Environmental Challenges

  • Continued business disruption from inflation, supply chain issues, labor shortages, commodity price increases (including due to the war in Ukraine), and lingering effects of the COVID-19 pandemic.
  • Dependence on strategic partnerships for research, development, and commercialization.
  • Lengthy and expensive clinical drug development process with uncertain timelines and outcomes.
  • Regulatory approval processes are lengthy, time-consuming, and unpredictable.
  • Complex mRNA-based medicine manufacturing.
  • Reliance on third parties for clinical trials and other tasks.
  • Uncertainty regarding governmental, private health insurer, and third-party payor coverage and reimbursement for product candidates.
  • Competition from other companies developing similar products.
  • Potential for undesirable side effects from product candidates.
  • Limited financial and managerial resources.
  • Maintaining compliance with regulations as a public company.
  • Cyberattacks or other IT system failures.
  • Managing growth and expansion.
  • ESG matters and related social expectations and concerns.
Mitigation Strategies
  • Implementing measures to remediate material weaknesses in internal control.
  • Establishing strategic partnerships.
  • Investing in manufacturing infrastructure and capabilities.
  • Focusing on specific product candidates and indications.
  • Implementing security measures to protect IT systems and data.
  • Developing disaster recovery and business continuity plans.
  • Improving managerial, operational, and financial systems.
  • Recruiting and training additional qualified personnel.
  • Monitoring and responding to ESG developments.

Supply Chain Management

Supplier Audits: Not disclosed

Responsible Procurement
  • Not disclosed

Climate-Related Risks & Opportunities

Physical Risks
  • Not disclosed
Transition Risks
  • Not disclosed
Opportunities
  • Not disclosed

Reporting Standards

Frameworks Used: IFRS

Certifications: Null

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

  • Not disclosed

Not disclosed

Sustainable Products & Innovation

  • Not disclosed

Awards & Recognition

  • Not disclosed

Reporting Period: 2023

Environmental Metrics

ESG Focus Areas

  • Sustainability
  • Ethical Behavior
  • Integrity
  • Human Rights
  • Environmental Protection

Governance Achievements

  • Established a Code of Conduct
  • Implemented a Whistleblowing Policy
  • Defined processes for handling conflicts of interest
  • Established data protection guidelines

Climate Goals & Targets

Supply Chain Management

Responsible Procurement
  • ESG compliance considered in supplier selection

Climate-Related Risks & Opportunities

Reporting Period: 2024

Environmental Metrics

ESG Focus Areas

  • Human Rights
  • Labor Standards
  • Ethics
  • Environmental Protection
  • Supply Chain Responsibility

Climate Goals & Targets

Supply Chain Management

Responsible Procurement
  • Compliance with this Supplier Code of Conduct
  • Adherence to applicable laws and regulations
  • Implementation of due diligence measures to prevent human rights or environmental violations

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: Pharmaceutical Industry Principles for Responsible Supply Chain Management, Ten Principles of the United Nations Global Compact, United Nations Guiding Principles on Business and Human Rights, OECD Guidelines for Multinational Enterprises, International Labour Organization conventions